Nurix Therapeutics, Inc. (NRIX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67080M1036
Nurix Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 83.98 m USD |
| Operating income | -285.67 m USD |
| EBIT | -263.70 m USD |
| Net income | -264.46 m USD |
| Diluted EPS – continuing operations | -3.05 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
More stocks
- Shanghai DZH Ltd (601519.SS)
- Liftoff Mobile, Inc. Common Stock (LFTO)
- Cushman & Wakefield Ltd. (CWK)
- Beijing Venustech Inc (002439.SZ)
- Asker Healthcare Group AB (ASKER.ST)
- Green Brick Partners, Inc. (GRBK)
- Angang Steel Co Ltd Class A (000898.SZ)
- Yantai North Andre Juice Co Ltd (605198.SS)
- Netcompany Group A/S (NETC.CO)
- HAWKINS INC (HWKN)
- MLOptic Corp. A (688502.SS)
- WuHu Foresight Technology Co.,Ltd. (301529.SZ)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.